Hasil Pencarian (15718)
Halaman 78 / 315BMS-188797 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, and Adult Acute Promyelocytic Leukemia (M3)…
BMS-275183 has been used in trials studying the treatment of Tumors and Non-small Cell Lung Cancer.
BMS-394136 has been used in trials studying the diagnostic of Heart Diseases.
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
BMS-582949 has been investigated for the treatment of Psoriasis.
BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.
BMS-690514 has been investigated for the treatment of Breast Cancer.
BMS-741672 is under investigation in clinical trial NCT00699790 (Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance).
BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).
BMS-770767 is under investigation in clinical trial NCT01058083 (Safety Study of BMS-770767 in Subjects With Hypercholesterolemia).
BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.
BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).
BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).
BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).
BMS-830216 is under investigation in clinical trial NCT00909766 (Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects).
Deskripsi belum tersedia.
BMS-863233 has been investigated for the treatment of Refractory Hematologic Cancer.
BMS-903452 has been used in trials studying the treatment of Diabetes.
BMS-908662 has been used in trials studying the treatment of Melanoma and Colorectal Cancer.
BMS-911543 has been used in trials studying the treatment of Cancer.
BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).
BMS-929075 is under investigation in clinical trial NCT01525212 (Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients).
BMS-955176 is under investigation in clinical trial NCT02415595 (Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults).
BMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).
BMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers).
INX-08189 has been used in trials studying the treatment of Hepatitis C, HCV (Genotype 1), and Hepatitis C Virus.
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
BMS-986115 has been used in trials studying the treatment of Various Advanced Cancer.
BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
BMS-986142 is under investigation in clinical trial NCT02880670 (Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects).
BMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).
BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis).
Deskripsi belum tersedia.
Deskripsi belum tersedia.
Deskripsi belum tersedia.
BN?Brachyury vaccine is a novel prime?boost therapeutic cancer immunotherapy. It is composed of the [MVA-BN-brachyury-TRICOM vaccine] and the fowlpox virus(FPV)?Brachyury booster vaccine.[A255173]
BNC-210 is under investigation in clinical trial NCT04951076 (A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-traumatic Stress Disorder (PTSD)).
Deskripsi belum tersedia.
BNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
BNT162a1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intram…
BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) …
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinica…
BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery v…